Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Goldman

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Health Service Journal|March 31, 2011
Hospital landscape. Why curiosity is a winning attitudeNeil Griffiths, John Drew, Mark Goldman
Pain Practice : the Official Journal of World Institute of Pain|December 15, 2006
Managing chronic-pain patients in the new millennium: clinical basis and regulatory viewpoint from Texas, U.S.AAnand W Mehendale, Donald Patrick, Mark Goldman
The Health Service Journal|May 10, 2011
Hospital landscape. Building bridges to improvementJohn Drew, Tom Revington, Mark Goldman, et al.
The FEBS Journal|July 5, 2006
Mixed-type noncompetitive inhibition of anthrax lethal factor protease by aminoglycosidesPetr Kuzmic, Lynne Cregar, Sherri Z Millis, et al.
Echocardiography (Mount Kisco, N.Y.)|June 9, 2012
Evaluation of cardiac involvement with mediastinal lymphoma: the role of innovative integrated cardiovascular imagingMark Goldman, Robert Matthews, Hong Meng, et al.
International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology|January 15, 2018
Developmental changes in the feedback related negativity from 8 to 14 yearsYael Arbel, Kayleigh N McCarty, Mark Goldman, et al.
Biologicals : Journal of the International Association of Biological Standardization|February 13, 2010
Validation and international regulatory experience for a mycoplasma touchdown PCR assayDavid Asarnow, Ann Warford, Lewis Fernandez, et al.
Bioorganic & Medicinal Chemistry Letters|August 17, 2002
Structure-activity relationship studies of ethyl 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: an inhibitor of AP-1 and NF-kappaB mediated gene expressionMoorthy S S Palanki, Leah M Gayo-Fung, Graziella I Shevlin, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Health Service Journal|March 31, 2011
Hospital landscape. Why curiosity is a winning attitudeNeil Griffiths, John Drew, Mark Goldman
Pain Practice : the Official Journal of World Institute of Pain|December 15, 2006
Managing chronic-pain patients in the new millennium: clinical basis and regulatory viewpoint from Texas, U.S.AAnand W Mehendale, Donald Patrick, Mark Goldman
The Health Service Journal|May 10, 2011
Hospital landscape. Building bridges to improvementJohn Drew, Tom Revington, Mark Goldman, et al.
The FEBS Journal|July 5, 2006
Mixed-type noncompetitive inhibition of anthrax lethal factor protease by aminoglycosidesPetr Kuzmic, Lynne Cregar, Sherri Z Millis, et al.
Echocardiography (Mount Kisco, N.Y.)|June 9, 2012
Evaluation of cardiac involvement with mediastinal lymphoma: the role of innovative integrated cardiovascular imagingMark Goldman, Robert Matthews, Hong Meng, et al.
International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology|January 15, 2018
Developmental changes in the feedback related negativity from 8 to 14 yearsYael Arbel, Kayleigh N McCarty, Mark Goldman, et al.
Biologicals : Journal of the International Association of Biological Standardization|February 13, 2010
Validation and international regulatory experience for a mycoplasma touchdown PCR assayDavid Asarnow, Ann Warford, Lewis Fernandez, et al.
Bioorganic & Medicinal Chemistry Letters|August 17, 2002
Structure-activity relationship studies of ethyl 2-[(3-methyl-2,5-dioxo(3-pyrrolinyl))amino]-4-(trifluoromethyl)pyrimidine-5-carboxylate: an inhibitor of AP-1 and NF-kappaB mediated gene expressionMoorthy S S Palanki, Leah M Gayo-Fung, Graziella I Shevlin, et al.
Pageof 2